Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality due to high risk for stroke, MI and related death. Lipid-lowering therapy with statins has been the major strategy, which has been shown to reduce major CV events. Despite catheter- and pharmacotherapy-based interventions, additional therapies are needed to reduce the rate of recurrent CV events.  Observed hs-CRP clearly predicted future CV events.  PCSK9 inhibitors and other human monoclonal antibodies with anti-inflammatory drugs reducing IL-6 and hs-CRP may overpower the lipid-lowering strategy.  Anti-inflammatory drugs might someday join the five-drug cocktail of aspirin, clopidogrel, angiotensin-converting enzyme inhibitor (ACEI) statins and b-blockers.